Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,732 across all filing types
Latest filing 2022-07-11 Regulatory Filings
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
111年6月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 美時, providing information about fund loans and endorsement guarantees for the month of June 2022 (民國111年06月). It contains tabulated data on loan balances and guarantee amounts but does not include comprehensive financial statements or detailed analysis. The document length is only 625 characters, indicating it is a short regulatory disclosure rather than a full report. There is no indication that this is an annual or interim report, audit report, or earnings release. It is also not a meeting-related document or a capital/financing update. Given the nature of the data and the brevity, this fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2022-07-11 Chinese
111年6月營業收入
Fund Information / Factsheet Classification · 90% confidence The document is a summary report of monthly and cumulative net operating revenue figures for a company named 美時 (Mei Shi) for the period 民國111年06月 (June 2022). It includes comparative figures from the previous year and percentage changes. The document is short (781 characters) and primarily presents financial summary data without detailed financial statements or analysis. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It also does not contain any narrative management discussion or detailed disclosures. The document resembles a brief financial factsheet or summary of key financial metrics. Therefore, the best fitting category is Fund Information / Factsheet (FS), which covers brief summaries of key company facts and financials.
2022-07-11 Chinese
公告本公司召開重大訊息記者會之新聞稿
Capital/Financing Update Classification · 95% confidence The document is a company announcement from 美時化學製藥股份有限公司 (company code 1795) dated 111/07/07 (Taiwan calendar year, roughly 2022). It announces a significant investment and financing activity involving a $25 million investment in special shares of a subsidiary of Alvogen Pharma Limited, along with details about the financing round led by financial investors. The content focuses on capital investment, shareholding structure, and financing terms. The document length is short (1485 characters) and it is not a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the financing event itself. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-07-07 Chinese
公告本公司取得New Alvogen Group Holdings, Inc.特別股股權
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by a listed company (1795 美時) regarding the acquisition of preferred shares in New Alvogen Group Holdings, Inc. It details the transaction specifics such as the number of shares, price, dividend rate, conversion rights, relationship between parties, decision process, and accounting firm involved. The document is short (2314 characters) and focuses on a specific capital transaction rather than financial results or management commentary. It does not contain financial statements or comprehensive financial data. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2022-07-07 Chinese
代子公司Lotus International Pte. Ltd依「公開發行公司資金 貸與及背書保證處理準則」第二十五條第一項第二、三、四款之 規定公告
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement from a listed company (美時) regarding a guarantee provided by its subsidiary Lotus International Pte. Ltd. It details the amounts, conditions, and financial ratios related to the guarantee. The content is a specific disclosure about financial guarantees and related credit information, not a full financial report or earnings release. The document length is short (1244 characters) and it is a formal announcement of a financial guarantee event under regulatory rules. This fits best under Regulatory Filings (RNS) as it is a compliance disclosure that does not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2022-07-06 Chinese
公告本公司111年股東常會決議解除董事競業禁止之限制
Board/Management Information Classification · 95% confidence The document is a public announcement from a listed company (1795 美時) regarding a resolution passed at the shareholders' meeting on 111/06/30 (June 30, 2022 in ROC calendar) to lift restrictions on directors engaging in competitive business activities. It details the names and titles of directors allowed to engage in competitive activities, the scope of such activities, and the voting results of the shareholders' meeting. This is a formal announcement of a board/management related decision made at a shareholders' meeting, specifically about directors' competitive activities. It is not a full report, financial statement, or earnings release, nor is it a voting result announcement or proxy solicitation. It fits best under Board/Management Information (MANG) as it concerns changes or permissions related to board members' activities.
2022-06-30 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.